Phase 2 N=296 Therapy for Pediatric Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Hodgkin's Lymphoma
Primary: 3-year Event-Free Survival Probability — 0.887 probability — p=0.9970
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Phase 2 N=34 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Complete Response Rate — 34 Participants
N/A N=1,598 B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
Classical Hodgkin Lymphoma · Relapsed or Refractory Classical Hodgkin Lymphoma
Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months
Phase 2 N=96 Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Non-Hodgkin's Lymphoma
Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients
N/A N=41 Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
Hodgkin Lymphoma, Adult
Primary: Percentage of Patients With Positron Emission Tomography (PET) Negative Disease — 37 Participants
N/A N=20 Proton Therapy for Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Comparison of Normal Tissue Exposed to Greater Than or Equal to 4 Gy/CGE With Use of Proton Therapy Compared to Both Intensity Modulated Radiotherapy (IMRT) and…
Phase 2 N=39 Rituximab in Treating Patients With Hodgkin's Lymphoma
Lymphoma · Hodgkin Lymphoma (Category) · Nodular Lymphocyte Predominant Hodgkin Lymphoma
Primary: Progression-free Survival (PFS) — 18 participants
Phase 2 N=82 Rituximab and ABVD for Hodgkin's Patients
Lymphoma
Primary: 5-year Failure-free Survival Rate for Participants With Hodgkin's Disease Given Rituximab With ABVD — 83 percentage of participants
Phase 2 N=23 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Phase 2 N=37 Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk
Hodgkin Lymphoma
Primary: Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of Nivolumab as Maintenance Therapy — 33 Participants
Phase 2 N=101 Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
Lymphoma
Primary: Progression-free Survival at 36 Months — 93.1; 89.7 percentage of participants — p=0.9669
Phase 3 N=1,334 A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF) — NA; NA months — p=0.035
Phase 2 N=96 Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Relapsed/Refractory Classical Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) Assessed According to the Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) by the Independent…
Phase 2 N=76 Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
Lymphoma, Hodgkin Disease · Lymphoma · Hodgkin Disease
Primary: Progression-free Survival (PFS) — 89.7; 50 percentage of participants
Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
N/A N=39 Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease
Lung Cancer
Primary: To Prospectively Collect Data on Chest CT Screening for Patients at Increase Lung-cancer Risk After Hodgkin's Disease. — 0 participants
Phase 2 N=68 EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Lymphoma, AIDS-related · Lymphoma, Large B-Cell, Diffuse
Primary: Median Progression Free Survival (PFS) — 13.8 years
Phase 3 N=854 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
Lymphoma
Primary: Failure-free Survival at 5 Years — 0.74; 0.71 Proportion of patients — p=0.32
Phase 2 N=49 Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma · Adult Mixed Cellularity Hodgkin Lymphoma
Primary: Complete Remission Rate After Chemotherapy — 38 Participants
Phase 2 N=50 Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Hodgkin Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Progression Free Survival (PFS) — 6.6 months
Phase 3 N=166 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma · Stage III Childhood Hodgkin Lymphoma · Stage IV Childhood Hodgkin Lymphoma
Primary: Second-event-free Survival — 0.91 Probability of survival
Phase 2 N=75 PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
Hodgkin Lymphoma, Adult
Primary: ORR Assess by IRC — 76.0 percentage
Phase 3 N=287 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
Childhood Favorable Prognosis Hodgkin Lymphoma · Childhood Lymphocyte Depletion Hodgkin Lymphoma · Childhood Mixed Cellularity Hodgkin Lymphoma
Primary: Event Free Survival Without Receiving Radiation Therapy (EFSnoRT). — 0.49 Probability of survival
Phase 2 N=67 Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
Lymphoma
Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants
Phase 2 N=50 Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Lymphoma
Primary: Effect of Rituximab on EBV(+) Tumors — 0 relapses
Phase 2 N=25 Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Overall Response Rate — 20.0 percentage of participants
Phase 2 N=35 Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma · Diffuse Large Cell Lymphoma · Mantle Cell Lymphoma
Primary: Event-free Survival (EFS) — 83 percentage of not experiencing EFS event
Phase 2 N=371 S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Lymphoma · Nonneoplastic Condition
Primary: Percentage of HIV-negative Patients With 2-year Progression-free Survival (PFS) Treated With 2 Initial Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine…